1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Entia Biosciences, Inc.

Entia Biosciences, Inc.

ERGO
Entia Biosciences, Inc.US flagOther OTC
0.00
USD
- -
- -
6,732.00Market Cap
Entia Biosciences, Inc.
ERGO
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2008
2009
2010
2011
2012
2013
2014
2015
2016
TTM
FRC
- -
- -
- -
0.01
0.07
0.06
0.05
0.04
0.07
0.01
- -
0.01
Revenue per Share
- -
- -
-0.04
-0.18
-0.24
-0.28
-0.18
-0.42
-0.24
-0.09
- -
-0.05
Basic EPS, GAAP
- -
- -
-0.1
-0.12
-0.11
-0.04
-0.05
-0.11
-0.07
-0.02
- -
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
-0.02
-0.19
-0.43
-0.64
-0.73
-1.13
-1.14
-0.54
- -
-0.51
Book Value per Share
- -
0.01
0.14
0.02
-0.07
-0.06
-0.11
-0.17
-0.05
-0.04
- -
-0.08
Tangible Book Value per Share
1
5
3
5
5
6
7
8
9
24
- -
28
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-1,377.34
-264.69
-338.88
-292.65
-851.98
-269.82
-552.29
-439.75
-439.74
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
-1
-2
-1
-3
-2
-2
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-1,370.83
-331.45
-428.7
-342.33
-986.45
-349.91
-651.48
-525.79
-525.78
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-1
-1
-1
-1
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
-1
-1
- -
-1
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
1
1
2

Working Capital

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
2
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
167.16%
148.56%
Free Cash Flow
788.94%
32.16%
29.46%
Net Income, GAAP
401.14%
10.57%
-38.24%
Sales/Revenue/Turnover
- -
2.94%
-23.48%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
1
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.06
-0.06
-0.06
- -
-0.24
2015
-0.05
-0.05
-0.01
- -
-0.09
2016
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
Similar Companies
Shire plc (SHPG)
Sundrug Co.,Ltd. (SDGCF)
Jenkem Technology Co., Ltd. (688356.SS)
Royalty Pharma plc (RPRX)
Captor Therapeutics Spolka Akcyjna (CTX.WA)
Muromachi Chemicals Inc. (4885.T)
Business
Entia Biosciences, Inc. (ERGO) develops and commercializes patented pharmaceutical-grade organic compounds derived from whole foods for use in medical foods, nutraceuticals, dietary supplements, and cosmeceuticals; its core portfolio includes ErgoD2, a foundational compound combining micro-nutrients, L-Ergothioneine (a master antioxidant amino acid), and vitamin D to enhance iron absorption and combat oxidative stress; the company also offers products targeting chronic kidney disease and other conditions under the GROH brand for beauty and health applications, with distribution primarily through e-commerce, direct email marketing, and social media channels in the United States. Founded in 2007 and headquartered in Sherwood, Oregon, Entia operates in the biotechnology sector, focusing on organic health, beauty, agriculture, and functional ingredients for branded products. The company, formerly known as Total Nutraceutical Solutions, Inc., changed its name in January 2012 and maintains a lean structure with approximately seven employees under CEO Timothy Timmins.